AR033293A1 - Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos - Google Patents

Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos

Info

Publication number
AR033293A1
AR033293A1 ARP020101595A ARP020101595A AR033293A1 AR 033293 A1 AR033293 A1 AR 033293A1 AR P020101595 A ARP020101595 A AR P020101595A AR P020101595 A ARP020101595 A AR P020101595A AR 033293 A1 AR033293 A1 AR 033293A1
Authority
AR
Argentina
Prior art keywords
increase
biodisponibility
compositions
methods
pharmaceutical agents
Prior art date
Application number
ARP020101595A
Other languages
English (en)
Inventor
Elizabeth Everitt
Edward Han
Sajeev Cherian
Dale Kempf
Hing L Sham
Shi-Chung Ng
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR033293A1 publication Critical patent/AR033293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para aumentar la biodisponibilidad de agentes farmacéuticamente activos. Se usa lopinavir, sus equivalentes aceptables para uso farmacéutico y derivados del mismo como inhibidores de la glicoproteína P.
ARP020101595A 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos AR033293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36735301P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
AR033293A1 true AR033293A1 (es) 2003-12-10

Family

ID=23446823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101595A AR033293A1 (es) 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos

Country Status (10)

Country Link
US (1) US20020198160A1 (es)
EP (1) EP1387684A1 (es)
JP (1) JP2005511481A (es)
AR (1) AR033293A1 (es)
CA (1) CA2445967A1 (es)
MX (1) MXPA03010054A (es)
PE (1) PE20021075A1 (es)
TW (1) TWI231211B (es)
UY (1) UY27275A1 (es)
WO (1) WO2002087585A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1713478A1 (en) * 2004-01-30 2006-10-25 Pfizer Inc. Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor
BRPI0512526A (pt) 2004-06-23 2008-03-11 Synta Pharmaceuticals Corp composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
CA2604907A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
JP2009504740A (ja) 2005-08-16 2009-02-05 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）製剤
NZ575350A (en) 2006-08-21 2012-02-24 Synta Pharmaceuticals Corp Bis(phenylcarbonothioyl)hydrazide derivatives
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US7645904B2 (en) * 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
EP2451445B1 (en) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
PT2608792T (pt) * 2010-08-26 2018-01-15 Boehringer Ingelheim Int Métodos de administração de um inibidor de egfr
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
PE20021075A1 (es) 2002-12-07
MXPA03010054A (es) 2004-04-02
TWI231211B (en) 2005-04-21
CA2445967A1 (en) 2002-11-07
US20020198160A1 (en) 2002-12-26
EP1387684A1 (en) 2004-02-11
JP2005511481A (ja) 2005-04-28
WO2002087585A1 (en) 2002-11-07
UY27275A1 (es) 2002-11-29

Similar Documents

Publication Publication Date Title
AR033293A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
SV2008001369A (es) Benzimidazoles
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
EA200870545A1 (ru) Новые гетероциклические соединения
DK0991407T4 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
PT1513826E (pt) Novos derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos potentes
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
ECSP083351A (es) Composiciones farmacéuticas
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
AR031152A1 (es) Tratamientos nuevos para el sindrome de piernas inquietas
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb
PA8644701A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal